Relmada provides 2024 outlook: REL-1017 study 302 ~50% enrolled; psilocybin Phase 1 planned

RELMADA THERAPEUTICS, INC.

REL-1017 Phase 3 study 302 (Reliance II) is approximately 50% enrolled (target ~300 patients); full enrollment expected H1 2024.
REL-1017 Phase 3 study 304 (Relight) enrollment to complete by year-end 2024, also ~300 patients.
Phase 1 trial of modified-release psilocybin (REL-P11) in obese patients with steatotic liver disease to start H1 2024; Phase 2a data expected H1 2025.
Dr. Cedric O'Gorman steps down as CMO; Dr. Andrew Cutler appointed Senior Clinical Development Advisor to support NDA process.
Cash runway expected to extend beyond all 2024 catalysts; no specific cash balance disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.